Bioprocess Technology Market

Bioprocess Technology Market Outlook (2024 to 2034)

According to this detailed industry analysis done by experienced analysts at Fact.MR, the global bioprocess technology market size is estimated at US$ 30.7 billion in 2024. Worldwide demand for bioprocess technologies is projected to increase at a CAGR of 14.8% and reach a market value of US$ 121.9 billion by 2034.

The growing focus on preventive measures, along with alternative medicines for specific uses, is driving up the need for effective bioprocess technologies. New pharma production sites and the expansion of existing facilities in emerging markets are key factors positively influencing overall bioprocess technology market growth.

The global bioprocess technology business space has evolved remarkably in the past half-decade on the back of increasing investments in new technologies to overcome performance and quality issues associated with the manufacturing of bioprocess products.

Shifting preferences toward bio-based products derived from biodegradable and fossil fuels are some of the notable bioprocess technology market trends. Cell culture bioprocess technology is the most significant type adopted across the world. Demand for bioprocess technologies in hospitals and research labs is set to increase at a significant pace over the coming years.

• The North American bioprocess technology market size is anticipated to reach a valuation of US$ 7.3 billion in 2024.
• East Asia is forecast to capture 23.1% of the global bioprocess technology market share by 2034.

Report Attribute	Detail
Bioprocess Technology Market Size (2024E)	US$ 30.7 Billion
Forecasted Market Value (2034F)	US$ 121.9 Billion
Global Market Growth Rate (2024 to 2034)	14.8% CAGR
South Korea Market Value (2034F)	US$ 6.5 Billion
Canada Market Growth Rate (2024 to 2034)	15.3% CAGR
Key Companies Profiled	MilliporeSigma; Danher Life Sciences; GE Healthcare; Roche Holding AG; Selvita Krakow; Fujifilm Healthcare; Catalent; Lonza- Pharma & biotech; Thermo Fisher Scientific; Sartorius Stedim Biotech; Asahi Kasei Medical; Boehringer Ingelheim; Solesis Medical (Fenner PLC); Dickinson and Company; Bio-Rad Laboratories; Charles River Laboratories; Corning; Eppendorf; Repligen; Rentschler Biopharma SE.

Bioprocess Technology Demand Forecasts (2024 to 2034)

• Short Term (2024 to 2027): Leading companies will focus on investments for the production of next-gen bioprocess technologies.
• Mid Term (2027 to 2030): Rising prevalence of chronic disorders and increasing demand for bio-based drugs will boost overall market growth.
• Long Term (2030 to 2034): In the long run, bioprocess technologies are expected to find widespread applications in the production of advanced vaccines and recombinant proteins.

Which Dynamics are Influencing the Market for Bioprocess Technologies?

“Rising Cases of Chronic Disorders Necessitating Need for Advanced Bioprocess Technologies for Effective Drug Production”

Primary reason behind the swift progress of bioprocess technology can be attributed to the evolution of the biopharmaceutical and biotechnology industries. The increasing prevalence of chronic diseases is also one of the main factors driving the sales of bioprocess technologies. The upsurge in demand for new drugs also initiates the need for advanced bioprocess technologies. Additionally, personalized treatment for diseases such as cancer is intensifying the demand for various bioprocess therapies, including cell therapy.

The importance of research & development in the life sciences industry is strongly promoted. Another rapidly growing bioprocess technology field is oligosaccharide manufacturing. Due to the uncountable health benefits of treating chronic diseases, they are finding numerous promising applications.

Which Aspects are Hampering Demand Growth for Bioprocess Technologies?

“Strict Regulations and High Costs Associated with Bioprocess Technologies”

Increasing safety concerns related to bioprocess technologies are hampering overall market growth to some extent. Careless handling of bioprocess technologies can lead to serious health hazards. Governments across the world are implementing strict regulations on the use of bioprocess technologies.

Large-scale bio production is costly compared to non-bioprocess technologies. This is attributed to factors such as labor-intensive operation, time-consuming processes, and the requirement of high funds. Protein purification is one of the bioprocesses that is the most cost-intensive.

Start-Up Ecosystem

• Singapore-based start-up SingCell provides process development services for stem cell therapy. The start-up is gaining popularity for its cost-effective stem cell production.
• British start-up CellulaREvolution is focused on the continuous bioprocessing paradigm. Peptide coating and bioreactors are two technologies provided by CellulaREvolution. The company’s solutions offer scale-up bio manufacturing and inline single-cell quality assurance.

Country-wise Analysis

Why is the United States a Key Market for Bioprocess Technology Providers?

“High Prevalence of Chronic Disorders Driving Demand for Advanced Bio-based Drugs”

Attribute	United States
Market Value (2024E)	US$ 3.3 Billion
Growth Rate (2024 to 2034)	15.3% CAGR
Projected Value (2034F)	US$ 13.5 Billion

The United States is estimated to account for 44.5% of the North American market share in 2024. Increasing requirements for upstream bioprocess equipment in the country are boosting the profits of bioprocess technology providers. The presence of industry giants, the rising prevalence of chronic disorders, and high investments in the advancements of biotechnologies are contributing to the overall growth of the bioprocess technology market in the United States.

Which European Country is a Profitable Market for Bioprocess Technology Providers?

“Germany Handsomely Leading Sales of Bioprocess Technologies in Europe”

Rising inclination towards bio-based medicines is the prime factor behind the high demand for bioprocess technologies in Germany. Other factors such as reduced and reuse of wastage are also fuelling the need for advanced bioprocess technologies in the country.

What is the Demand Outlook for Bioprocess Technologies in Japan?

“Rapidly Evolving Pharma Sector Boosting Adoption of Bioprocess Technologies”

Attribute	Japan
Market Value (2024E)	US$ 2 Billion
Growth Rate (2024 to 2034)	15.4% CAGR
Projected Value (2034F)	US$ 8.3 Billion

Increasing production of biopharmaceuticals such as vaccines and recombinant proteins is driving the demand for bioprocess technologies in Japan. The country is leading in the field of biotechnology. Single-use consumables are increasing the application of bioprocess technologies in Japan’s pharma sector.

Category-wise Analysis

Which is the Most Preferred Type of Bioprocess Technology?

“Cell Culture Crucial Technique in Cellular and Molecular Biology for Investigation of Diseased Cells”

Bioprocess technologies are holding the most significant positions in the healthcare industry. Cell culture bioprocessing is the most prominent bioprocessing technology type. Rising investments in research and development activities are also proliferating demand for cell culture bioprocess technologies. Cell culture is used as a model system for studying basic cell biology and biochemistry. Biological studies on the effect of drugs, the process of aging, and the interaction between cells and disease-causing agents such as bacteria and viruses are significantly fuelling cell culture bioprocess technology demand.

Which is an Important Application Area of Bioprocess Technologies?

“Increasing Demand for Innovative Drugs Boosting Use of Bioprocess Technologies in Biopharmaceutical Sector”

Attribute	Biopharmaceuticals
Segment Value (2024E)	US$ 10.4 Billion
Growth Rate (2024 to 2034)	14.5% CAGR
Projected Value (2034F)	US$ 40.1 Billion

The biopharmaceutical sector is witnessing high growth due to rising healthcare expenditures across the globe. Innovative drugs for sustained patient outcomes are anticipated to play a key role in the growth of the bio-pharmaceuticals sector. Looking into the demand trend, manufacturers of biopharmaceuticals are focusing on increasing their production to cater to high market requirements.

Competitive Landscape

Key players in the bioprocess technology industry are focusing on market expansion by following both, inorganic and organic approaches. Industry giants are also harnessing public-private funding for research and development activities. These moves are helping market players offer next-gen bioprocess technologies.

• In March 2022, Stämm Biotech closed a US$ 17 million Series A funding deal for its next-generation 3-D printer bioreactor.
• In October 2022, Thermo Fisher Scientific Inc. announced the launch of the 'DynaSpin Single-Use Centrifuge System', a large-scale cell culture harvesting solution.
• In May 2022, GOOD Meat joined hands with ABEC to design, manufacture, install, and commission widely known bioreactors for mammalian and avian cell culture under an exclusive multi-year agreement.
• In 2017, GE Healthcare acquired Puridify, a bioprocessing start-up that develops nanofiber-based platform purification technology for the production of biopharmaceuticals. Puridify's FibroSelect technology complements the bead resins and chromatography membranes that are utilized in downstream bioprocessing processes today, achieving faster mass transfer & scalability, and ease of use.

Fact.MR provides detailed information about the price points of key providers of bioprocess technologies positioned across the world, sales growth, production capacity, and speculative technological expansion, in the recently updated market report.

Key Segments of Bioprocess Technology Market Research

• By Type :

  • Cell Culture
  • Cell Expansion
  • Flow Cytometry
  • Cell Line Development
  • Virus Infiltration

• By Application :

  • Biopharmaceuticals
  • Specialty Products
  • Industry Chemicals
  • Environment Management Aids

• By End User :

  • Hospitals
  • Research Labs
  • Medical Institutions

• By Region :

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • East Asia
  • South Asia & Pacific
  • Middle East & Africa